{"id":829698,"date":"2026-08-11T16:33:03","date_gmt":"2026-08-11T16:33:03","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=829698"},"modified":"2026-08-11T16:33:03","modified_gmt":"2026-08-11T16:33:03","slug":"clinical-trial-services-market-to-reach-usd-10186-billion-by-2030-driven-by-decentralized-trials-and-rising-rd-investments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/clinical-trial-services-market-to-reach-usd-10186-billion-by-2030-driven-by-decentralized-trials-and-rising-rd-investments_829698.html","title":{"rendered":"Clinical Trial Services Market to Reach USD 101.86 Billion by 2030, Driven by Decentralized Trials and Rising R&D Investments"},"content":{"rendered":"
\"Clinical<\/a><\/div>\n
Clinical Trial Services Market by Type (Laboratory, Monitoring, Recruitment, PV, Data Management), Phase (I, II, III), Therapy (Oncology, Neurology, Dermatology, CVD), Modality (Biologics, Devices), Delivery Model (FSP, Hybrid) – Global Forecast to 2030<\/div>\n

According to MarketsandMarkets™, <\/strong>The global clinical trial services market<\/a><\/strong> is projected to grow from USD 66.59 billion in 2025 to USD 101.86 billion by 2030, registering a CAGR of 8.9% during the forecast period. The market is being driven by increasing pharmaceutical and biotechnology R&D investments, growing adoption of patient-centric and decentralized clinical trials (DCTs), rising demand for personalized medicine, and increasing outsourcing of clinical development activities to contract research organizations (CROs).<\/p>\n

Browse 661 market data Tables and 61 Figures spread through 521 Pages and in-depth TOC on “Clinical Trial Services Market “.<\/strong><\/p>\n

Download PDF Brochure: https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=405<\/a><\/strong><\/p>\n

Pharmaceutical companies facing patent expirations are intensifying investments in drug development and increasingly relying on CROs for flexible, scalable, and specialized clinical trial services. CROs are incorporating artificial intelligence, real-world data (RWD), adaptive trial designs, and digital technologies to improve trial efficiency, accelerate timelines, and enhance patient engagement.<\/p>\n

The growing focus on pediatric clinical trials, diversity in clinical trial populations, and the use of RWD to support regulatory submissions is creating additional opportunities for clinical trial service providers. However, cybersecurity risks associated with AI-enabled data processing, patient data protection concerns, and patient retention challenges in long-duration and decentralized trials remain key market challenges.<\/p>\n

Small Molecules Segment Holds Largest Market Share<\/strong><\/p>\n

By modality, the clinical trial services market is segmented into small molecules, biologics, and medical devices. The small molecules segment accounted for the largest share during the forecast period.<\/p>\n

The continued dominance of small molecules is supported by their established role across drug development programs and their broad application across therapeutic areas. Their oral administration, stability, cost-effectiveness, and ability to target intracellular pathways make small molecules attractive for pharmaceutical companies and patients.<\/p>\n

Although biologics and advanced therapies are experiencing rapid development, the established clinical development ecosystem for small molecules is expected to sustain their leading position in the clinical trial services market.<\/p>\n

Oncology Segment Dominates Therapy Areas<\/strong><\/p>\n

By therapy area, oncology accounted for the largest share of the clinical trial services market in 2024. The segment’s dominance is primarily attributed to the rising global cancer burden, aging populations, and increasing demand for innovative cancer treatments.<\/p>\n

Pharmaceutical and biotechnology companies are increasing investments in oncology pipelines and partnering with CROs to manage complex clinical development programs. Growing development of targeted therapies, immunotherapies, biologics, and other advanced oncology treatments is expected to sustain demand for specialized clinical trial services throughout the forecast period.<\/p>\n

Asia Pacific Registers Fastest Growth<\/strong><\/p>\n

Asia Pacific is expected to register the highest CAGR in the clinical trial services market during the forecast period. The region’s growth is supported by its large and diverse patient population, rising prevalence of chronic and infectious diseases, expanding clinical research infrastructure, and increasing development of biologics, biosimilars, and advanced therapies.<\/p>\n

Global pharmaceutical companies are increasingly expanding clinical research activities in Asia Pacific to leverage cost advantages, improving regulatory environments, growing research capabilities, and access to diverse patient populations. Government initiatives and increasing investments in clinical research are also encouraging the outsourcing of clinical trial activities across countries in the region.<\/p>\n

North America maintained the largest market share in 2024, supported by its established pharmaceutical and biotechnology ecosystem, advanced clinical research infrastructure, and strong presence of leading CROs.<\/p>\n

Request Sample Pages: https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=405<\/a><\/strong><\/p>\n

CROs Accelerate Digital Transformation in Clinical Research<\/strong><\/p>\n

The growing complexity of clinical trials is encouraging CROs to expand their technology-enabled service offerings. AI-powered data analysis, decentralized trial platforms, remote patient monitoring, real-world evidence, electronic data capture, and adaptive trial methodologies are increasingly being incorporated into clinical development programs.<\/p>\n

These technologies can help sponsors improve patient recruitment and retention, optimize trial operations, enhance data quality, and potentially accelerate clinical development timelines. At the same time, ensuring robust cybersecurity, regulatory compliance, and protection of sensitive patient information remains critical for market participants.<\/p>\n

Competitive Landscape<\/strong><\/p>\n

Key players in the clinical trial services market include IQVIA Inc., Thermo Fisher Scientific Inc., Fortrea, ICON Plc, Syneos Health, Laboratory Corporation of America Holdings, Medpace, WuXi AppTec, Frontage Labs, Pharmaron, Tigermed, SGS Société Générale de Surveillance SA, Eurofins Scientific, Linical, Parexel International Corporation, Worldwide Clinical Trials, Novotech, PSI, Allucent, Premier Research, Clario, KCR S.A., Rho, Inc., and Advanced Clinical, among others.<\/p>\n

These companies are focusing on expanding global delivery capabilities, strengthening therapeutic expertise, adopting AI and digital technologies, and developing flexible delivery models such as functional service provider (FSP) and hybrid models to meet the evolving needs of pharmaceutical and biotechnology companies.<\/p>\n

Related Reports:<\/strong><\/p>\n

Active Pharmaceutical Ingredient Market<\/a> – Global Forecast to 2030<\/strong><\/p>\n

Contract Research Organization (CRO) Services Market<\/a> – Global Forecast to 2031<\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> MarketsandMarkets\u2122 Research Private Ltd.<\/a>
Contact Person:<\/strong> Mr. Rohan Salgarkar
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18886006441
Address:<\/strong>1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City:<\/strong> Florida
State:<\/strong> Florida
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.marketsandmarkets.com\/Market-Reports\/clinical-trials-market-405.html<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Clinical Trial Services Market by Type (Laboratory, Monitoring, Recruitment, PV, Data Management), Phase (I, II, III), Therapy (Oncology, Neurology, Dermatology, CVD), Modality (Biologics, Devices), Delivery Model (FSP, Hybrid) – Global Forecast to 2030 According to MarketsandMarkets™, The global clinical trial … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,411,404],"tags":[],"class_list":["post-829698","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Technology","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/829698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=829698"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/829698\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=829698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=829698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=829698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}